DEA acts against designer synthetic drug linked to 151 overdose deaths since 2015

DEA has taken action against a designer synthetic cathinone associated with more than 150 overdose deaths in the United States since 2015. The DEA action, published in the Federal Register, places N-Ethylpentylone into Schedule I of the Controlled Substances Act.

DEA has taken action against a designer synthetic cathinone associated with more than 150 overdose deaths in the United States since 2015. The DEA action, published in the Federal Register, places N-Ethylpentylone into Schedule I of the Controlled Substances Act. According to DEA Acting Administrator Uttam Dhillon, putting the drug in Schedule I is important to avoid an imminent public safety risk. The temporary scheduling action lasts for 2 years, with an additional year possible while investigating whether the drug should be controlled permanently. Last year, DEA labs identified almost 3,000 fentanyl and fentanyl-related compound exhibits, 922 synthetic cannabinoid exhibits, and 369 cathinone exhibits. Of those cathinone exhibits, 201 of those were N-Ethylpentylone. Adverse effects linked to abuse of the synthetic drug include insomnia, hyperthermia, vomiting, agitation, disorientation, paranoia, abdominal pain, cardiac arrest, respiratory failure, coma, and death.